Oscar Health (OSCR) stock closed up 22% on Nov. 24 after a political A report says President Donald Trump’s administration is considering a two-year extension of Affordable Care Act (ACA) subsidies.
The US government’s next health policy framework will add new limits on income (up to 700% of the federal poverty line) and introduce minimum premium payments to curb rising costs, the report added.
Despite today’s rally, Oscar Health stock is still down about 30% from its year-to-date high.
A two-year extension of ACA subsidies will be significantly positive for OSCR stock, as the New York-based company primarily operates in the Affordable Care Act markets.
The expanded income limits will expand eligibility, meaning more customers will potentially be able to access subsidized coverage.
Meanwhile, minimum premium requirements will help stabilize prices, reducing the risk of sharp cost increases that often drive members away.
Together, these measures can strengthen enrollment, improve retention, and provide Oscar Health with greater revenue visibility.
For a company that depends on political support for its growth, the indicated framework improves both demand and investor confidence, which is why the shares rose today.
Despite the expected extension of Obamacare, Oscar Health stock remains unattractive as a long-term holding because the insurance company has yet to achieve sustainable profitability.
Investors are warned not to chase OSCR’s momentum also because it failed to overcome a key resistance coinciding with its 100-day moving average (MA) at today’s $17 level.
This suggests that the broader downtrend for the NYSE-listed company remains intact.
Historically (over the past four years), healthcare technology stocks have plunged more than 10% in December, further strengthening the case to capitalize on the strength and dump OSCR on Monday.
Wall Street analysts also recommend selling Oscar Health shares at current levels.
According to Barchart, the consensus rating on OSCR stock remains at “Moderate Sell” with an average target of less than $13, indicating a potential drop of over 20% from here.